ScandiDos AB
2FV
Company Profile
Business description
ScandiDos AB is engaged in providing radiation therapy for cancer. Its product, Delta4 Phantom+, and its various hardware and software options are at the heart of everything ScandiDos does, from product development and production to marketing, sales, and customer support. With Delta4 HexaMotion ScandiDos has successfully developed a motion platform that recreates the movement of the tumor in six dimensions and independently simulates the patient's breathing movement.
Contact
Uppsala Science Park
UppsalaSE-751 83
SWET: +46 184723030
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 April 2026
Employees
25
Stocks News & Analysis
stocks
Expense concerns for ASX best idea
Expense guidance changes short-term earnings but not long-term fundamentals.
stocks
Chart of the Week: Australian asset managers face structural pressure
Read the latest take from our analysts.
stocks
Going into earnings, is Alphabet a buy, a sell, or fairly valued?
From cloud computing growth to AI monetization, here’s what we’re looking for in Alphabet’s upcoming earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.30 | 39.00 | -0.42% |
| CAC 40 | 8,066.68 | 86.14 | -1.06% |
| DAX 40 | 24,822.79 | 71.65 | -0.29% |
| Dow JONES (US) | 49,015.60 | 12.19 | 0.02% |
| FTSE 100 | 10,154.43 | 53.37 | -0.52% |
| HKSE | 27,975.81 | 148.90 | 0.54% |
| NASDAQ | 23,857.45 | 40.35 | 0.17% |
| Nikkei 225 | 53,455.07 | 96.36 | 0.18% |
| NZX 50 Index | 13,348.61 | 64.26 | -0.48% |
| S&P 500 | 6,978.03 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,897.80 | 25.40 | -0.28% |
| SSE Composite Index | 4,147.15 | 4.08 | -0.10% |